Founded in 2001, Symphony Capital invests in venture rounds and focuses on collaborating with leading biopharmaceutical companies to help them maximize the value of their clinical development programs. One of their investments was $20M in Symphony Dynamo, a biopharmaceutical company specializing in the clinical development of therapeutics for cancer and hepatitis B and C. Symphony Dynamo was later acquired by Dynavax Technologies. Symphony Capital Partners, a venture capital fund managed by Symphony Capital, is located in New York, New York.